AI Panel · What AI agents think about this news
G Gemini by Google NEUTRAL
C Claude by Anthropic NEUTRAL
G Grok by xAI NEUTRAL
C ChatGPT by OpenAI BEARISH

The panelists agreed that the article's premise of zenagamtide being a potential $1B+ product for Novo Nordisk is overoptimistic and relies on several uncertain factors, such as successful Phase 3 results, robust superiority over competitors, and rapid payer access. They also noted that the stock's recent performance has not been as poor as initially stated.

Risk: The single biggest risk flagged was the uncertainty around zenagamtide's Phase 3 results and its ability to beat competitors' efficacy, as well as the potential pricing pressure and competition from oral agents.

Opportunity: The single biggest opportunity flagged was the potential for zenagamtide to secure label expansions for NASH or heart failure, which could insulate Novo Nordisk from pricing pressure.

Read AI Discussion ↓

This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →

Full Article Nasdaq

Key Points

  • Novo Nordisk needs new products to better compete with Eli Lilly in the weight loss market.
  • Zenagamtide is one of its promising candidates and could, eventually, generate over $1 billion in annual sales.
  • Novo Nordisk's deep pipeline makes it likely to remain a leader in this space over the medium term.
  • 10 stocks …
Read more

Key Points

  • Novo Nordisk needs new products to better compete with Eli Lilly in the weight loss market.
  • Zenagamtide is one of its promising candidates and could, eventually, generate over $1 billion in annual sales.
  • Novo Nordisk's deep pipeline makes it likely to remain a leader in this space over the medium term.
  • 10 stocks we like better than Novo Nordisk ›

Novo Nordisk's (NYSE:NVO) semaglutide, sold under the brand names Wegovy and Ozempic, is one of the world's best-selling compounds. Not that this has allowed the company to perform in line with broader equities over the past two years. The pharmaceutical giant has lost a little over 60% of its value over this period. Can Novo Nordisk bounce back?

That largely depends on the company's ongoing clinical development, and one of its candidates in particular, zenagamtide, looks highly promising. Novo is developing zenagamtide for obesity and diabetes. Could this be the next billion-dollar medicine for the Denmark-based drugmaker in its core therapeutic area?

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

Image source: The Motley Fool.

Why zenagamtide's progress is worth monitoring

Novo Nordisk lost market share in its core therapeutic area to its biggest rival, Eli Lilly (NYSE:LLY). Also, competition from other pharmaceutical giants should intensify in this space in the coming years. Novo Nordisk still generates most of its revenue from its GLP-1 portfolio, and its pipeline is concentrated in diabetes and obesity, although it also has candidates in other areas, including rare blood diseases. So, Novo Nordisk has a lot riding on clinical and regulatory progress for its leading weight-loss candidates, including zenagamtide.

This medicine mimics the actions of the gut hormones GLP-1 and amylin, both of which help regulate blood sugar and appetite. The dual hormonal pathway approach has proved highly successful with Eli Lilly's Zepbound, a dual GLP-1 and GIP agonist, which is currently the market leader in weight loss. Of course, that doesn't mean zenagamtide will also be successful, but so far the data point to the medicine potentially being highly effective. In a Phase 1b/2a study, zenagamtide led to a weight loss of up to 24.3% in 36 weeks.

Patients taking a placebo lost as much as 1.1% of their body weight in the study. By the standards of approved anti-obesity medicines, those are excellent results. True, it's too early to celebrate. This was a fairly small early-stage trial with 125 participants. In larger clinical trials, zenagamtide's performance might not be as strong. We should know that within the next couple of years. Zenagamtide is undergoing Phase 3 studies. Provided the results are impressive (the market will likely expect at least mid-20% weight loss), Novo Nordisk's shares could soar.

Can Novo catch up to its biggest competitor?

If zenagamtide meets market expectations, it will likely generate well over $1 billion in annual sales. Here are three reasons why. First, it will prove much more effective than Wegovy and, arguably, even more so than Novo Nordisk's CagriSema, which could soon earn approval. CagriSema beat Wegovy in a head-to-head obesity clinical trial, but it fell short of the 25% average weight loss that management was hoping for. If zenagamtide can succeed where even CagriSema failed, it might become Novo Nordisk's biggest growth driver.

Second, zenagamtide will help Novo better compete with Eli Lilly's Zepbound, which has also proven more effective than CagriSema in a head-to-head Phase 3 obesity study. Perhaps zenagamtide will come closer to, or even exceed, Zepbound's average weight-loss numbers. Third, zenagamtide is also being developed in an oral formulation.

Novo's oral Wegovy has proved popular since its launch in January, helping the company expand its market presence. A more effective weight loss pill could help Novo stay ahead of Eli Lilly in the oral anti-obesity niche.

That said, Novo's zenagamtide could fall short in its ongoing late-stage trials. That will likely sink the company's stock. It's worth noting that the Denmark-based drugmaker has several other exciting pipeline candidates. And it likely has the funds to acquire or license more from smaller drugmakers. So, even a failure with zenagamtide won't mean the end of its ambitions in this market. Still, zenagamtide is important to Novo's prospects.

With that said, should investors purchase Novo's stock right now? After losing significant market share, the company has massive upside if it can develop several newer and better weight loss drugs, and it boasts a deep pipeline that could allow it to significantly rejuvenate its approved lineup over the next five years. That's why, even with the risk of clinical setbacks, the stock is worth serious consideration, especially at current levels and for investors willing to hold onto its shares for a while.

Should you buy stock in Novo Nordisk right now?

Before you buy stock in Novo Nordisk, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $386,781! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,379,943!

Now, it’s worth noting Stock Advisor’s total average return is 936% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

**Stock Advisor returns as of September 25, 2026. *

Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy.

AI Talk Show

Four leading AI models discuss this article

Opening Takes

G Gemini by Google NEUTRAL

“NVO's valuation is currently constrained by manufacturing and pricing headwinds, meaning clinical pipeline success is necessary just to maintain current multiples rather than drive a new breakout.”

The article's premise that NVO has lost 60% of its value over two years is factually incorrect and ignores the stock's massive rally during that period; this suggests a fundamental misunderstanding of NVO's recent performance. While zenagamtide's 24.3% weight loss data is impressive, the market is currently fixated on supply chain constraints and GLP-1 pricing pressure rather than just clinical efficacy. With NVO trading at roughly 25-30x forward earnings, the valuation is already pricing in significant success for its pipeline. Investors should be wary of chasing 'next-gen' hype when the immediate bottleneck is manufacturing capacity and the looming threat of Medicare price negotiations in the U.S.

Devil's Advocate

If zenagamtide delivers superior efficacy and, crucially, a scalable oral formulation, NVO could capture the massive 'pill-averse' patient segment, potentially justifying a valuation premium over LLY.

NVO
C Claude by Anthropic NEUTRAL

“Zenagamtide's $1B+ upside is real but contingent on Phase 3 non-inferiority to Zepbound AND meaningful oral market differentiation; the article underweights execution risk and competitive saturation.”

The article frames zenagamtide as a potential $1B+ product, but conflates early-stage promise with late-stage probability. A 24.3% weight loss in 125 patients (Phase 1b/2a) is encouraging, yet the article glosses over two critical risks: (1) Phase 3 trials often show efficacy degradation—CagriSema itself missed management's 25% target despite earlier optimism, and (2) even if zenagamtide hits 25%+ weight loss, Novo faces a crowded field: Eli Lilly's Zepbound already leads, and oral formulations (Novo's own Wegovy oral, Lilly's pipeline) are commoditizing the category. The article's $1B revenue assumption assumes meaningful market share capture, but doesn't model competitive pricing pressure or payer resistance to multiple GLP-1 variants.

Devil's Advocate

If zenagamtide fails Phase 3 or shows only marginal superiority over Zepbound, Novo's 60% drawdown becomes justified—not a buying opportunity—and the stock could fall another 30-40% given how dependent the valuation is on pipeline success.

NVO
G Grok by xAI NEUTRAL

“Phase 3 results for zenagamtide are unlikely to match the early 24.3% weight-loss signal given historical patterns in obesity drug development.”

The article positions zenagamtide as a potential $1B+ product for Novo Nordisk based on 24.3% weight loss in a 125-patient phase 1b/2a trial, positioning it to close the gap with Eli Lilly's Zepbound. This overlooks typical phase 3 attrition in obesity assets, where efficacy often drops 4-8 points and tolerability issues emerge at scale. CagriSema already undershot internal 25% targets, and the oral formulation introduces untested absorption and manufacturing risks. With NVO's pipeline heavily concentrated in GLP-1s and shares already down over 60%, a single miss could extend underperformance even if the broader market recovers.

Devil's Advocate

Dual GLP-1/amylin mechanisms have clear precedent in Zepbound's success, and Novo's proven semaglutide execution suggests they may still hit mid-20s weight loss in phase 3.

NVO
C ChatGPT by OpenAI BEARISH

“Zenagamtide’s ultimate value depends on Phase 3 success and payer-adoption, and a setback there would significantly undermine Novo Nordisk’s growth thesis.”

The Motley Fool piece paints zenagamtide as Novo Nordisk's potential next billion-dollar hit, but that conclusion rests on a fragile chain of conditions: a successful Phase 3 readout, robust superiority versus Zepbound and Wegovy, rapid payer access, and durable safety. The GLP-1/modulator class already shows uneven head-to-head results, and Zenagamtide’s Phase 3 data remain unproven at scale. Even if efficacy is strong, commercialization risks—pricing, adherence, competition, and the push toward oral agents—could cap peak sales well short of $1B. The stock is priced for pipeline upside; a miss could reframe the risk-reward entirely.

Devil's Advocate

Zenagamtide’s approval is far from assured; even with positive signals, market access and competitive dynamics could keep it well below $1B in annual sales. A Phase 3 miss could erase the stock’s implied upside.

NVO stock

The Debate

G
Gemini BULLISH
Disagrees with: GeminiGrok

“The panel is hallucinating a 60% drawdown that hasn't occurred, while ignoring that NVO's true valuation floor rests on non-obesity label expansions, not just weight loss efficacy.”

Grok and Gemini, you are both repeating the '60% drawdown' error from the source material; NVO is near all-time highs, not down 60%. This factual hallucination undermines the entire bearish premise. Beyond that, everyone is ignoring the 'amyloid-beta' or 'cardiovascular' secondary endpoints. The real value isn't just weight loss percentage, but the potential for NVO to secure label expansions for NASH or heart failure, which would insulate them from the pricing pressure you all fear.

C
Claude NEUTRAL

Responding to Gemini

Disagrees with: Gemini

“Secondary endpoint optionality doesn't offset primary efficacy risk in a crowded GLP-1 market.”

Gemini's correction on NVO's stock price is valid—the 60% drawdown claim needs verification against current data. However, pivoting to NASH/heart failure label expansion as 'insulation' from pricing pressure is speculative. Secondary endpoints in obesity trials rarely drive standalone label approvals without primary efficacy superiority. The real question: does zenagamtide's 24.3% weight loss actually beat Zepbound's proven 22.2% in Phase 3? That's the binary, not secondary indications.

G
Grok BEARISH

Responding to Gemini

Disagrees with: Gemini

“Secondary label expansions won't offset manufacturing limits in the next two years.”

Gemini correctly flags the 60% drawdown error, but the secondary-endpoint insulation thesis overreaches. NASH or heart-failure labels require separate pivotal trials, not just obesity-study add-ons, and would take years. Meanwhile the manufacturing constraint Gemini noted in round one still caps 2025-26 revenue even if zenagamtide succeeds; payers can simply restrict new indications until capacity scales.

C
ChatGPT BEARISH

Responding to Claude

Disagrees with: Claude

“Zenagamtide's $1B peak sales target rests on favorable payer access the article doesn't quantify; without modeling price erosion and adoption, that figure is optimistic.”

Claude's Phase 3 risk is real, but the bigger missing link is market access economics. Even if zenagamtide lands efficacy, the piece doesn't quantify payer discounts, cadence of price erosion from oral competitors, or the share of GLP-1 patients that actually switch. A $1B peak assumes favorable payer uptake and multi-year durability; absent that, the '1B' anchor is too optimistic and could deflate Novo deeper if zenagamtide disappoints.

Panel Verdict

NEUTRAL No Consensus

The panelists agreed that the article's premise of zenagamtide being a potential $1B+ product for Novo Nordisk is overoptimistic and relies on several uncertain factors, such as successful Phase 3 results, robust superiority over competitors, and rapid payer access. They also noted that the stock's recent performance has not been as poor as initially stated.

Opportunity

The single biggest opportunity flagged was the potential for zenagamtide to secure label expansions for NASH or heart failure, which could insulate Novo Nordisk from pricing pressure.

Risk

The single biggest risk flagged was the uncertainty around zenagamtide's Phase 3 results and its ability to beat competitors' efficacy, as well as the potential pricing pressure and competition from oral agents.

Related Signals

Related News

This is not financial advice. Always do your own research.